{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n LINC00565 is a long non‐coding RNA that has emerged as a multifaceted oncogenic regulator across several cancer types. In glioblastoma, for example, LINC00565 is part of a prognostic six‐lncRNA signature that is associated with key pathways—such as focal adhesion, extracellular matrix receptor interaction, and MAPK signaling—suggesting its potential role in tumor progression and patient risk stratification."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n In ovarian cancer, LINC00565 is markedly upregulated and correlates with unfavorable clinical features. Functional studies have shown that its high expression promotes cell proliferation, invasion, and migration by facilitating cell cycle progression through upregulation of CyclinD1, CyclinE1, and CDK4 while suppressing cell cycle inhibitors such as P16 and P21. Moreover, LINC00565 has been implicated in the upregulation of the oncogene GAS6, thereby aiding tumor progression."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n In endometrial carcinoma, elevated levels of LINC00565 correlate with larger tumor size, advanced pathological stage, and poor prognosis. Mechanistic investigations revealed that it enhances cellular proliferation by downregulating the transcription factor KLF9, with knockdown studies demonstrating marked inhibition of proliferative capacity and tumor growth in vivo."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "4"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n In gastric cancer, LINC00565 functions as a competing endogenous RNA by sponging miR‐665, which leads to an increase in AKT3 expression. This molecular interaction contributes to enhanced proliferative and colony formation abilities while reducing apoptosis, thereby facilitating tumor development."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "6"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Similarly, in colorectal cancer, the upregulation of LINC00565 is associated with advanced tumor stage and larger tumor size. Here, LINC00565 predominantly localizes in the cytoplasm and binds to EZH2, a key epigenetic regulator, thereby promoting cell proliferation and migration. Rescue experiments further underscore its role in aggravating tumor aggressiveness."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "7"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Collectively, these studies underscore the oncogenic role of LINC00565—it exerts its effects through diverse molecular mechanisms, including modulation of cell cycle regulators, acting as a competitive endogenous RNA, and interacting with epigenetic modifiers. Its consistent upregulation in various cancers and clear associations with poor prognostic features make LINC00565 a promising biomarker for cancer diagnosis and a potential target for personalized therapeutic strategies.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Ruqing Liang, Yaqin Zhi, Guizhi Zheng, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Analysis of long non-coding RNAs in glioblastoma for prognosis prediction using weighted gene co-expression network analysis, Cox regression, and L1-LASSO penalization."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Onco Targets Ther (2018)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2147/OTT.S171957"}], "href": "https://doi.org/10.2147/OTT.S171957"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30613154"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30613154"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Mi Gong, Chengyan Luo, Huangyang Meng, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Onco Targets Ther (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2147/OTT.S227758"}], "href": "https://doi.org/10.2147/OTT.S227758"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31819497"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31819497"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Na Li, Xianquan Zhan "}, {"type": "b", "children": [{"type": "t", "text": "Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "EPMA J (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s13167-020-00209-y"}], "href": "https://doi.org/10.1007/s13167-020-00209-y"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32549918"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32549918"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Xiuyan Yin, Xiaohong Li, Guijiao Feng, et al. "}, {"type": "b", "children": [{"type": "t", "text": "LINC00565 Enhances Proliferative Ability in Endometrial Carcinoma by Downregulating KLF9."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Onco Targets Ther (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2147/OTT.S249133"}], "href": "https://doi.org/10.2147/OTT.S249133"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32636642"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32636642"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Unknown Authors "}, {"type": "b", "children": [{"type": "t", "text": "Erratum: Upregulated LINC00565 Accelerates Ovarian Cancer Progression by Targeting GAS6 [Corrigendum]."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Onco Targets Ther (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2147/OTT.S242712"}], "href": "https://doi.org/10.2147/OTT.S242712"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32099390"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32099390"}]}, {"type": "r", "ref": 6, "children": [{"type": "t", "text": "Jianghong Hu, Guohua Ni, Ling Mao, et al. "}, {"type": "b", "children": [{"type": "t", "text": "LINC00565 promotes proliferation and inhibits apoptosis of gastric cancer by targeting miR-665/AKT3 axis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Onco Targets Ther (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2147/OTT.S189471"}], "href": "https://doi.org/10.2147/OTT.S189471"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31576144"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31576144"}]}, {"type": "r", "ref": 7, "children": [{"type": "t", "text": "Xiaxia Shao, Tao Zhao, Lei Xi, et al. "}, {"type": "b", "children": [{"type": "t", "text": "LINC00565 promotes the progression of colorectal cancer by upregulating EZH2."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Oncol Lett (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3892/ol.2020.12314"}], "href": "https://doi.org/10.3892/ol.2020.12314"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "33281964"}], "href": "https://pubmed.ncbi.nlm.nih.gov/33281964"}]}]}]}